Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury

Toxicological Sciences

Volumn 136, Issue 1, 2013, Pages 97-106

  Vinken, Mathieu ^a   Landesmann, Brigitte ^b   Goumenou, Marina ^b   Vinken, Stefanie ^c   Shah, Imran ^d   Jaeschke, Hartmut ^e   Willett, Catherine ^f   Whelan, Maurice ^b   Rogiers, Vera ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b JOINT RESEARCH CENTRE   (Italy)

^c Algemeen Stedelijk Ziekenhuis   (Belgium)

^d Environmental Protection Agency (EPA)   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f Humane Society of the United States   (United States)

Author keywords

Adverse outcome pathway.; Cholestasis; Drug induced liver injury

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILE SALT; BILIRUBIN; BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADVERSE OUTCOME; ADVERSE OUTCOME PATHWAY; ARTICLE; CELL MEMBRANE; CHOLESTASIS; DOSE RESPONSE; HUMAN; HYPERBILIRUBINEMIA; INFLAMMATION; JAUNDICE; OXIDATIVE STRESS; RISK ASSESSMENT; TOXIC HEPATITIS;

ADVERSE OUTCOME PATHWAY.; CHOLESTASIS; DRUG-INDUCED LIVER INJURY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTASIS, INTRAHEPATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; MODELS, BIOLOGICAL; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TOXICOLOGY;

EID: 84884178912     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft177     Document Type: Article

References (98)

1. Allen, K., Jaeschke, H., and Copple, B. L. (2011). Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. Am. J. Pathol. 178, 175-186.
2. Andersen, M. E., Clewell, R., and Bhattacharya, S. (2012). Developing in vitro tools sufficient by themselves for 21st century risk assessment. In Towards the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing. (T. Gocht and M. Schwarz, Eds.), Vol. 2, pp. 347-360. Imprimerie Mouzet, Perreux sur Marne, France.
3. Andersen, M. E., McMullen, P. D., and Bhattacharya, S. (2013). Toxicogenomics for transcription factor-governed molecular pathways: Moving on to roles beyond classification and prediction. Arch. Toxicol. 87, 7-11.
4. Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., et al. (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730-741.
5. Barbier, O., Torra, I. P., Sirvent, A., Claudel, T., Blanquart, C., Duran-Sandoval, D., Kuipers, F., Kosykh, V., Fruchart, J. C., and Staels, B. (2003). FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activity. Gastroenterology 124, 1926-1940.
6. Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K., and Garewal, H. (2005). Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589, 47-65.
7. Bogdanffy, M. S., Daston, G., Faustman, E. M., Kimmel, C. A., Kimmel, G. L., Seed, J., and Vu, V. (2001). Harmonization of cancer and noncancer risk assessment: Proceedings of a consensus-building workshop. Toxicol. Sci. 61, 18-31.
8. Botla, R., Spivey, J. R., Aguilar, H., Bronk, S. F., and Gores, G. J. (1995). Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: A mechanism of UDCA cytoprotection. J. Pharmacol. Exp. Ther. 272, 930-938.
9. Boyer, J. L., Trauner, M., Mennone, A., Soroka, C. J., Cai, S. Y., Moustafa, T., Zollner, G., Lee, J. Y., and Ballatori, N. (2006). Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1124-G1130.
10. Boyer, L. B. (2009). Adaptive regulation of hepatocyte transporters in cholestasis. In The Liver: Biology and Pathobiology, 5th ed. (I. M. Arias, H. J. Alter, J. L. Boyer, D. E. Cohen, N. Fausto, D. A. Shafritz and A. W. Wolkoff, Eds.), pp. 681-702. Wiley-Blackwell, Oxford, UK.
11. Björnsson, E., and Olsson, R. (2005). Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481-489.
12. Blomme, E. A., Yang, Y., and Waring, J. F. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 186, 22-31.
13. Chen, H. L., Chen, H. L., Liu, Y. J., Feng, C. H., Wu, C. Y., Shyu, M. K., Yuan, R. H., and Chang, M. H. (2005). Developmental expression of canalicular transporter genes in human liver. J. Hepatol. 43, 472-477.
14. Cheng, X., Buckley, D., and Klaassen, C. D. (2007). Regulation of hepatic bile acid transporters NTCP and Bsep expression. Biochem. Pharmacol. 74, 1665-1676.
15. Cherrington, N. J., Slitt, A. L., Li, N., and Klaassen, C. D. (2004). Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32, 734-741.
16. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2011). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138.
17. Denson, L. A., Sturm, E., Echevarria, W., Zimmerman, T. L., Makishima, M., Mangelsdorf, D. J., and Karpen, S. J. (2001). The orphan nuclear receptor, SHP, mediates bile acid-induced inhibition of the rat bile acid transporter, NTCP. Gastroenterology 121, 140-147.
18. Echchgadda, I., Song, C. S., Oh, T., Ahmed, M., De La Cruz, I. J., and Chatterjee, B. (2007). The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21, 2099-2111.
19. Eloranta, J. J., and Kullak-Ublick, G. A. (2005). Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433, 397-412.
20. EU. (2003). Directive 2003/15/EC of the European parliament, of the council of 27 February amending council directive 76/768/EEC on the approximation of the laws of the member states relating to cosmetic products. OV. J. L. 066, 26-35.
21. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231.
22. Faucette, S. R., Sueyoshi, T., Smith, C. M., Negishi, M., Lecluyse, E. L., and Wang, H. (2006). Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317, 1200-1209.
23. Feingold, K. R., Spady, D. K., Pollock, A. S., Moser, A. H., and Grunfeld, C. (1996). Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J. Lipid Res. 37, 223-228.
24. Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., and Gasser, R. (2001). Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167, 83-98.
25. Gnerre, C., Blättler, S., Kaufmann, M. R., Looser, R., and Meyer, U. A. (2004). Regulation of CYP3A4 by the bile acid receptor FXR: Evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14, 635-645.
26. Gollamudi, R., Gupta, D., Goel, S., and Mani, S. (2008). Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr. Drug Metab. 9, 611-613.
27. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000). A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517-526.
28. Gores, G. J., Miyoshi, H., Botla, R., Aguilar, H. I., and Bronk, S. F. (1998). Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: A potential role for mitochondrial proteases. Biochim. Biophys. Acta 1366, 167-175.
29. Green, R. M., Hoda, F., and Ward, K. L. (2000). Molecular cloning and characterization of the murine bile salt export pump. Gene 241, 117-123.
30. Gu, X., Ke, S., Liu, D., Sheng, T., Thomas, P. E., Rabson, A. B., Gallo, M. A., Xie, W., and Tian, Y. (2006). Role of NF-kappaB in regulation of PXRmediated gene expression: A mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem. 281, 17882-17889.
31. Gujral, J. S., Farhood, A., Bajt, M. L., and Jaeschke, H. (2003). Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 38, 355-363.
32. Gujral, J. S., Liu, J., Farhood, A., Hinson, J. A., and Jaeschke, H. (2004). Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G499-G507.
33. Heuman, D. M. (1989). Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J. Lipid Res. 30, 719-730.
34. Hill, A. B. (1965). The environment and disease: Association or causation? Proc. R. Soc. Med. 58, 295-300.
35. Hofmann, A. F. (2009). Bile acids and the enterohepatic circulation. In The Liver: Biology and Pathobiology (I. M. Arias, H. J. Alter, J. L. Boyer, D. E. Cohen, N. Fausto, D. A. Shafritz, and A. W. Wolkoff, Eds.), pp. 289-304, Wiley-Blackwell, Oxford, UK.
36. Jaeschke, H., and Hasegawa, T. (2006). Role of neutrophils in acute inflammatory liver injury. Liver Int. 26, 912-919.
37. Jara, P., Hierro, L., Martínez-Fernández, P., Alvarez-Doforno, R., Yánez, F., Diaz, M. C., Camarena, C., De la Vega, A., Frauca, E., Muñoz-Bartolo, G., et al. (2009). Recurrence of bile salt export pump deficiency after liver transplantation. N. Engl. J. Med. 361, 1359-1367.
38. Jemnitz, K., Veres, Z., and Vereczkey, L. (2010). Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol. Sci. 115, 80-88.
39. Julien, E., Boobis, A. R., and Olin, S. S.; Ilsi Research Foundation Threshold Working Group. (2009). The Key Events Dose-Response Framework: A cross-disciplinary mode-of-action based approach to examining doseresponse and thresholds. Crit. Rev. Food Sci. Nutr. 49, 682-689.
40. Jung, D., Elferink, M. G., Stellaard, F., and Groothuis, G. M. (2007). Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27, 137-144.
41. Jung, D., Mangelsdorf, D. J., and Meyer, U. A. (2006). Pregnane X receptor is a target of farnesoid X receptor. J. Biol. Chem. 281, 19081-19091.
42. Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., and Edwards, P. A. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-2915.
43. Keitel, V., Burdelski, M., Vojnisek, Z., Schmitt, L., Häussinger, D., and Kubitz, R. (2009). De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: A novel mechanism of cholestasis. Hepatology 50, 510-517.
44. Kim, M. S., Shigenaga, J., Moser, A., Grunfeld, C., and Feingold, K. R. (2004). Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 287, E731-E738.
45. Kis, E., Ioja, E., Rajnai, Z., Jani, M., Méhn, D., Herédi-Szabó, K., and Krajcsi, P. (2012). BSEP inhibition: In vitro screens to assess cholestatic potential of drugs. Toxicol. In Vitro 26, 1294-1299.
46. Knisely, A. S., Strautnieks, S. S., Meier, Y., Stieger, B., Byrne, J. A., Portmann, B. C., Bull, L. N., Pawlikowska, L., Bilezikçi, B., Ozçay, F., et al. (2006). Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44, 478-486.
47. Kocarek, T. A., Shenoy, S. D., Mercer-Haines, N. A., and Runge-Morris, M. (2002). Use of dominant negative nuclear receptors to study xenobioticinducible gene expression in primary cultured hepatocytes. J. Pharmacol. Toxicol. Methods 47, 177-187.
48. Kostrubsky, V. E., Vore, M., Kindt, E., Burliegh, J., Rogers, K., Peter, G., Altrogge, D., and Sinz, M. W. (2001). The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab. Dispos. 29, 1561-1566.
49. Krasowski, M. D., Yasuda, K., Hagey, L. R., and Schuetz, E. G. (2005). Evolution of the pregnane x receptor: Adaptation to cross-species differences in biliary bile salts. Mol. Endocrinol. 19, 1720-1739.
50. Kuntz, E., and Kuntz, H. D. (2008). Cholestasis. In Hepatology: Textbook and Atlas: History, Morphology, Biochemistry, Diagnostics, Clinic, Therapy (E. Kuntz and E. H-D. Kuntz, Eds.), 3rd ed. pp. 235-250. Springer, Heidelberg, Germany.
51. Landesmann, B., Goumenou, M., Munn, S., and Whelan, M. (2012). Description of prototype modes-of-action related to repeated dose toxicity. JRC Scientific and Policy Report 75689.
52. Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., Kullak-Ublick, G. A., Meier, P. J., and Pauli-Magnus, C. (2007). Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17, 47-60.
53. Lang, T., Haberl, M., Jung, D., Drescher, A., Schlagenhaufer, R., Keil, A., Mornhinweg, E., Stieger, B., Kullak-Ublick, G. A., and Kerb, R. (2006). Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab. Dispos. 34, 1582-1599.
54. Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L. B., and Schuetz, J. D. (2000). Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/Pglycoprotein. Mol. Pharmacol. 57, 24-35.
55. Lee, J., Azzaroli, F., Wang, L., Soroka, C. J., Gigliozzi, A., Setchell, K. D., Kramer, W., and Boyer, J. L. (2001). Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 121, 1473-1484.
56. Li, F., Patterson, A. D., Krausz, K. W., Tanaka, N., and Gonzalez, F. J. (2012). Metabolomics reveals an essential role for peroxisome proliferator-activated receptor a in bile acid homeostasis. J. Lipid Res. 53, 1625-1635.
57. Li-Masters, T., and Morgan, E. T. (2001). Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab. Dispos. 29, 252-257.
58. Lucena, M. I., Andrade, R. J., Kaplowitz, N., García-Cortes, M., Fernández, M. C., Romero-Gomez, M., Bruguera, M., Hallal, H., Robles-Diaz, M., Rodriguez-González, J. F., et al.; Spanish Group for the Study of Drug-Induced Liver Disease. (2009). Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology 49, 2001-2009.
59. Maher, J. M., Cheng, X., Slitt, A. L., Dieter, M. Z., and Klaassen, C. D. (2005). Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33, 956-962.
60. Mazzon, E., and Cuzzocrea, S. (2003). Role of iNOS in hepatocyte tight junction alteration in mouse model of experimental colitis. Cell. Mol. Biol. 49, 45-57.
61. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33, 591-653.
62. Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., Nussler, N., Eichelbaum, M., Meier, P. J., and Stieger, B. (2006). Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44, 62-74.
63. Mennone, A., Soroka, C. J., Harry, K. M., and Boyer, J. L. (2010). Role of breast cancer resistance protein in the adaptive response to cholestasis. Drug Metab. Dispos. 38, 1673-1678.
64. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Jr, Lightfoot-Dunn, R., and Hamadeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485-500.
65. Morotti, R. A., Suchy, F. J., and Magid, M. S. (2011). Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: A review of the liver pathology findings. Semin. Liver Dis. 31, 3-10.
66. NRC. (2007). Toxicity testing in the 21st century: A vision and a strategy. The National Academies Press, Washington, DC.
67. OECD. (2011). Report of the workshop on using mechanistic information on forming chemical categories. Series on Testing and Assessment No. 138. Paris, France.
68. OECD. (2012a). Proposal for a template and guidance on developing and assessing the completeness of adverse outcome pathways, Paris, France. OECD. (2012b). The adverse outcome pathway for skin sensitization initiated by covalent binding to proteins part I: Scientific evidence. Series on Testing and Assessment No. 168. Paris, France.
69. OECD. (2012b). The adverse outcome pathway for skin sensitization initiated by covalent binding to proteins part I: Scientific evidence. Series on Testing and Assessment No. 168. Paris, France.
70. Oude Elferink, R. P., Paulusma, C. C., and Groen, A. K. (2006). Hepatocanalicular transport defects: Pathophysiologic mechanisms of rare diseases. Gastroenterology 130, 908-925.
71. Ozer, J., Ratner, M., Shaw, M., Bailey, W., and Schomaker, S. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194-205.
72. Padda, M. S., Sanchez, M., Akhtar, A. J., and Boyer, J. L. (2011). Drug-induced cholestasis. Hepatology 53, 1377-1387.
73. Pagani, R., Portolés, M. T., De La Viña, S., Melzner, I., and Vergani, G. (2003). Alterations induced on cytoskeleton by Escherichia coli endotoxin in different types of rat liver cell cultures. Histol. Histopathol. 18, 837-848.
74. Pauli-Magnus, C., and Meier, P. J. (2006). Hepatobiliary transporters and druginduced cholestasis. Hepatology 44, 778-787.
75. Pauwels, M., and Rogiers, V. (2010). Human health safety evaluation of cosmetics in the EU: A legally imposed challenge to science. Toxicol. Appl. Pharmacol. 243, 260-274.
76. Román, I. D., Monte, M. J., Gonzalez-Buitrago, J. M., Esteller, A., and Jiménez, R. (1990). Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: Relationship with cholestasis and hyperbilirubinemia. Hepatology 12, 83-91.
77. Salgia, R., Becker, J. H., and Sayeed, M. M. (1993). Altered membrane fluidity in rat hepatocytes during endotoxic shock. Mol. Cell. Biochem. 121, 143-148.
78. Schoemaker, M. H., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L., and Moshage, H. (2004). Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39, 1563-1573.
79. Seed, J., Carney, E. W., Corley, R. A., Crofton, K. M., DeSesso, J. M., Foster, P. M., Kavlock, R., Kimmel, G., Klaunig, J., Meek, M. E., et al. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 35, 664-672.
80. Sekine, S., Yano, K., Saeki, J., Hashimoto, N., Fuwa, T., and Horie, T. (2010). Oxidative stress is a triggering factor for LPS-induced MRP2 internalization in the cryopreserved rat and human liver slices. Biochem. Biophys. Res. Commun. 399, 279-285.
81. Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 110, 3507-3512.
82. Sokol, R. J., Dahl, R., Devereaux, M. W., Yerushalmi, B., Kobak, G. E., and Gumpricht, E. (2005). Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 41, 235-243.
83. Trauner, M., Arrese, M., Lee, H., Boyer, J. L., and Karpen, S. J. (1998a). Endotoxin downregulates rat hepatic NTCP gene expression via decreased activity of critical transcription factors. J. Clin. Invest. 101, 2092-2100.
84. Trauner, M., Meier, P. J., and Boyer, J. L. (1998b). Molecular pathogenesis of cholestasis. N. Engl. J. Med. 339, 1217-1227.
85. United States Environmental Protection Agency (US EPA). (2005). Guidelines for carcinogen risk assessment. US EPA, Washington, DC: Office of Research and Development, US Environmental Protection Agency.
86. Vinken, M., Pauwels, M., Ates, G., Vivier, M., Vanhaecke, T., and Rogiers, V. (2012). Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Arch. Toxicol. 86, 405-412.
87. Vuppalanchi, R., Chalasani, N., and Saxena, R. (2006). Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am. J. Surg. Pathol. 30, 1619-1623.
88. Wagner, M., Zollner, G., and Trauner, M. (2009). New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51, 565-580.
89. Woolbright, B. L., and Jaeschke, H. (2012). Novel insight into mechanisms of cholestatic liver injury. World J. Gastroenterol. 18, 4985-4993.
90. Yang, K., Köck, K., Sedykh, A., Tropsha, A., and Brouwer, K. L. (2013). An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 102, 3037-3057.
91. Yasumiba, S., Tazuma, S., Ochi, H., Chayama, K., and Kajiyama, G. (2001). Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats. Biochem. J. 354, 591-596.
92. Yoshikado, T., Takada, T., Yamamoto, T., Yamaji, H., Ito, K., Santa, T., Yokota, H., Yatomi, Y., Yoshida, H., Goto, J., et al. (2011). Itraconazole-induced cholestasis: Involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol. Pharmacol. 79, 241-250.
93. Zhang, Y., Hong, J. Y., Rockwell, C. E., Copple, B. L., Jaeschke, H., and Klaassen, C. D. (2012). Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int. 32, 58-69.
94. Zollner, G., Marschall, H. U., Wagner, M., and Trauner, M. (2006a). Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251.
95. Zollner, G., and Trauner, M. (2006). Molecular mechanisms of cholestasis. Wien. Med. Wochenschr. 156, 380-385.
96. Zollner, G., and Trauner, M. (2008). Mechanisms of cholestasis. Clin. Liver Dis. 12, 1-26.
97. Zollner, G., Wagner, M., Moustafa, T., Fickert, P., Silbert, D., Gumhold, J., Fuchsbichler, A., Halilbasic, E., Denk, H., Marschall, H. U., et al. (2006b). Coordinated induction of bile acid detoxification and alternative elimination in mice: Role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G923-G932.
98. Zollner, G., Wagner, M., and Trauner, M. (2010). Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther. 126, 228-243.